Enzymotec (ENZY) Given News Impact Rating of 0.18

Press coverage about Enzymotec (NASDAQ:ENZY) has trended somewhat positive recently, according to Accern Sentiment. The research firm ranks the sentiment of news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Enzymotec earned a news sentiment score of 0.18 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 44.3257853999536 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

A number of equities research analysts recently weighed in on ENZY shares. Wells Fargo & Co lifted their price objective on shares of Enzymotec from $9.50 to $12.00 and gave the company a “market perform” rating in a research note on Monday, October 30th. Jefferies Group reiterated a “hold” rating and issued a $11.50 price target on shares of Enzymotec in a research report on Thursday, October 19th. BidaskClub cut Enzymotec from a “hold” rating to a “sell” rating in a research note on Saturday, January 6th. Finally, Zacks Investment Research raised Enzymotec from a “strong sell” rating to a “hold” rating in a research note on Tuesday, October 17th. One investment analyst has rated the stock with a sell rating and four have issued a hold rating to the company. The stock has an average rating of “Hold” and an average price target of $11.75.

Shares of Enzymotec (ENZY) traded down $0.02 during midday trading on Monday, hitting $11.85. The company had a trading volume of 98,500 shares, compared to its average volume of 120,557. The company has a market cap of $277.62, a PE ratio of -43.89, a price-to-earnings-growth ratio of 3.19 and a beta of 1.22. Enzymotec has a 1-year low of $6.30 and a 1-year high of $12.35.

Enzymotec (NASDAQ:ENZY) last posted its earnings results on Wednesday, November 15th. The biotechnology company reported $0.04 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.07 by ($0.03). Enzymotec had a negative return on equity of 3.26% and a negative net margin of 12.32%. analysts expect that Enzymotec will post 0.05 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Enzymotec (ENZY) Given News Impact Rating of 0.18” was originally reported by BBNS and is the sole property of of BBNS. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The original version of this piece of content can be read at https://baseballnewssource.com/markets/enzymotec-enzy-given-media-sentiment-score-of-0-18/1817883.html.

Enzymotec Company Profile

Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company’s technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company’s segments offer a range of products that leverage its lipid-related offerings.

Insider Buying and Selling by Quarter for Enzymotec (NASDAQ:ENZY)

Receive News & Ratings for Enzymotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzymotec and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Houston Astros Add Starter to Rotation
Houston Astros Add Starter to Rotation
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Justin Morneau Former Star With Twins and AL MVP Retires
Justin Morneau Former Star With Twins and AL MVP Retires
MLB Rumor: Pirates Discussing Andrew McCutchen with Mets
MLB Rumor: Pirates Discussing Andrew McCutchen with Mets


Leave a Reply

 
© 2006-2018 BBNS.